금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
“Balance of risks to inflation remains to the upside” – BoE’s Lombardelli
Bank of England (BoE) Deputy Governor Clare Lombardelli warned that high energy costs could keep inf...
SMH enters the blue box: Is the next major rally about to begin?
Analysts remain constructive on semiconductors heading into the end of 2026. J.P. Morgan sees strong...
Apple, Meta, Iovance, Carnival, Fair Isaac, Bloom Energy, SpaceX, and More Stocks That Explain Today’s Market
Nvidia fell 0.3%, reversing from Monday’s gains when it announced a $150 billion expansion to its stock buyback plan and software to tackle the problem of AI safety. Navitas Semiconductor rose 1.1% ...
Good news for OpenAI is great news for Oracle’s stock — here’s why
Wall Street is cheering AI stocks as OpenAI gets closer to a revenue milestone.
Update: Equities Drop Intraday, Yields Rise as Traders Parse Macro Data
(Updates with latest market prices and developments.) US benchmark equity indexes were lower intr
What Is The Case For Waiting On CRM Stock?
Salesforce (CRM) stock has gained about 44% over the past three months, while the S&P 500 rose 3.5%. Investors entering at current levels are buying after a substantial run-up. Consequently, the valua ...
Six Flags closes X2 roller coaster, citing safety and guest confidence
OpenAI considering raising $30B in new funding at a $1.4T valuation: report
Dow Jones Software Leader Microsoft, Palantir, Micron, Palo Alto In Or Near Buy Zones
Dow Jones software giant Microsoft, along with Palantir, Micron and Palo Alto, are in or near buy zones in the current stock market.
New York Fed's Williams sees one more rate hike late this year
Too much AI hype risks fueling inflation, Chicago Fed's Goolsbee says
Sector Update: Energy Stocks Softer Tuesday Afternoon
Energy stocks fell Tuesday afternoon with the NYSE Energy Sector Index declining 1.1% and the State
CDC data now show two measles deaths for 2026; Pennsylvania records four
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson's specialty distribution, oncology and GLP-1 growth are driving earnings, while drug pricing, margin pressure and policy uncertainty pose challenges.